SERVICES

Cell line Development

Premas has deep __________ and established labs and ________ on bacterial, yeast and mammalian expression _________. Our cell lines for ___________ and clinical stage programs ___ high yield, well-characterised and _________ with the international regulatory __________ (ICH).

Bacterial Strain Development at ______

Premas utilizes our ____ experience in strain development ____________ to generate high expression _______ and vector combinations which ____ then be transferred as _____________ cell lines. Various classes __ proteins and candidate molecules ____ been taken forward for ________ studies using our bacterial ______ development capabilities.

Saccharomyces Cerevisiae Strain Development at ______

S cerevisiae cell line is _ PEP4/Prb1 protease deficient strain ___ has been consistently successful __ expression of membrane proteins ___ study of target proteins. S cerevisiae has also worked ____ with our proprietary expression _______ which are both Integrative ______ and Episomal series. Different _______ of membrane proteins that _____ from 2-24 transmembrane domains ____ been successfully expressed.

Pichia Cell Line Development __ Premas

Premas has a ____ established cell line development _______ to generate high expression ____ lines using Pichia pastoris strains and develop ____ into manufacturing cell lines. Various classes of proteins ___ candidate molecules have been _____ forward for IND __________ globally and clinical studies _____ our Pichia cell ____ development capabilities.

Premas CHO-DG44 Cell ____ Development at Premas

A proprietary, high-performance _________ cell line derived from ___ parent CHO-DG44 cells from ____. Chasin’s Lab at Columbia __________, NY, US. It has ____ used for the production __ reagent proteins, therapeutic recombinant ________, including monoclonal antibodies. The ____ line works best with ___ proprietary mammalian expression vectors, _____ are designed for high-level ______ expression in mammalian hosts. ___ growth and production properties __ our CHO-DG44 cell line ___ well defined, and the ____ strategy has been optimised, ________ for faster and more _________ scale-up to bioreactors. Gram _____ expression of antibodies per _____ level have been observed _____ this cell line and ___ therapeutic candidates have shown ___________ results, having reached preclinical _____.

The cell line ___ been adapted and made _________ to cGMP guidelines.